EU Pharma Rejects Proposed Changes To Orphan Medicine Criteria
Companies Want More Incentives For New Drug Development
The European Commission’s latest consultation on overhauling the EU legislation on medicines for children and for rare diseases has drawn some sharp responses from stakeholders.
